Nuvation Bio Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Nuvation Bio şirketinin kazançları yıllık ortalama -27.1% oranında azalırken, Pharmaceuticals sektörünün kazançları yıllık 13.5% oranında artan oldu. Gelirler yıllık ortalama 95.8% oranında artan oldu.
Anahtar bilgiler
-27.09%
Kazanç büyüme oranı
-17.68%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 5.95% |
| Gelir büyüme oranı | 95.76% |
| Özkaynak getirisi | -59.02% |
| Net Marj | -88.19% |
| Son Kazanç Güncellemesi | 30 Jun 2026 |
Yakın geçmiş performans güncellemeleri
Recent updates
Anlatı Güncellemesi • Aug 27
NUVB: Fast Track Glioma Program Will Drive Future Oncology Portfolio Upside
Analysts lifted their average price target on Nuvation Bio to $21.00, supported by fresh coverage that highlights perceived undervaluation, growing confidence in Ibtrozi and safusidenib, and updated assumptions around margins and future P/E. Analyst Commentary Recent research coverage on Nuvation Bio points to a cluster of positive views around the commercial ramp of Ibtrozi and the potential of safusidenib.Seeking Alpha • Aug 26
Nuvation: Why I'm Downgrading To Hold Despite Progress On NSCLC And Glioma Fronts
Summary Nuvation Bio Inc. is downgraded to Hold after a >200% share price run, reflecting cautious optimism amid early Ibtrozi launch dynamics. Ibtrozi, now the leading ROS1 TKI in new patient starts, posted $23.2m Q2 revenues with strong first-line uptake, but overall patient starts declined sequentially. NUVB management projects a $3.8bn Ibtrozi peak revenue opportunity, but current sales and analyst estimates suggest a more modest trajectory near $650m. Safusidenib offers promising pipeline potential in IDH1-mutant glioma yet faces entrenched competition and a lengthy path to approval. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Aug 13
NUVB: Safusidenib Glioma Data Will Drive Future Upside Potential
Analysts have nudged their average price target for Nuvation Bio higher from about $12.33 to roughly $13.11, citing recent safusidenib trial updates, upward revisions to individual targets as high as $21, and an expanded view of the long term glioma treatment opportunity. Analyst Commentary Recent Street research on Nuvation Bio focuses heavily on safusidenib data and how that might translate into future revenue potential and stock valuation.
Anlatı Güncellemesi • Jul 24
NUVB: Glioma Data And Lung Cancer Progress Will Shape Future Upside And Risks
Analysts have trimmed their fair value estimate for Nuvation Bio from $8.00 to $7.00 as they factor in a slightly higher discount rate, more moderate projected revenue growth, and updated views on long term profitability and future P/E, while also citing supportive safusidenib data and a revised $19 price target. Analyst Commentary on Nuvation Bio Recent research commentary on Nuvation Bio centers on updated safusidenib data and how that could influence long term valuation, especially in relation to the company’s revised fair value estimate and price target.Anlatı Güncellemesi • Jul 10
NUVB: UK Regulatory Progress For Lead Oncology Asset Will Drive Future Upside
Analysts have adjusted their fair value estimate for Nuvation Bio to $12.33 from $10.25, citing updated assumptions on discount rates, future profitability and P/E expectations, alongside recent sector commentary around biotech earnings and capital flows. What’s in the News for Nuvation Bio Nuvation Bio reported that partner Eisai’s Marketing Authorisation Application for taletrectinib in advanced ROS1-positive non small cell lung cancer was validated by the UK Medicines and Healthcare products Regulatory Agency, moving the therapy into formal UK regulatory review (source: company announcement and partner Eisai).Anlatı Güncellemesi • Jun 26
NUVB: Convertible Notes Raise Will Support Advancing Lead Oncology Portfolio
Analysts have lifted their price target on Nuvation Bio from about $16.80 to roughly $19.70, reflecting updated assumptions for revenue growth, profit margins, discount rate and future P/E that they see as better aligned with the company’s current outlook. What’s in the News for Nuvation Bio Nuvation Bio plans to raise up to US$230 million through a convertible senior notes offering maturing in 2032.Analiz Makalesi • May 08
Results: Nuvation Bio Inc. Confounded Analyst Expectations With A Surprise Profit
Investors in Nuvation Bio Inc. ( NYSE:NUVB ) had a good week, as its shares rose 8.1% to close at US$4.81 following the...Analiz Makalesi • May 17
Is Nuvation Bio (NYSE:NUVB) Using Debt In A Risky Way?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Seeking Alpha • Feb 13
Nuvation Bio: Pending Approval Shot In ROSL+ NSCLS Looks A Major Upside Catalyst
Summary Nuvation Bio, listed via SPAC in 2021, and acquired AnHeart Therapeutics last year, gaining taletrectinib, a promising ROS1 inhibitor indicated for NSCLC. The FDA has accepted Nuvation's New Drug Application for the drug, assigning it priority review and a PDUFA date of June 23, 2025. Taletrectinib shows clearly superior clinical data compared to rivals, with a potential market opportunity of ~$3.8bn by its fourth year, despite current market skepticism. Concerns include reliance on Chinese study data and competition from established pharma giants, but Nuvation's cash reserves suggest readiness for a wide-scale launch. Ahead of the PDUFA date, Nuvation presents a speculative investment opportunity, given it is potentially undervalued with a "blockbuster-in-waiting" drug candidate so close to approval, and further promising pipeline assets. Read the full article on Seeking AlphaAnaliz Makalesi • Nov 20
Is Nuvation Bio (NYSE:NUVB) Using Debt In A Risky Way?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Seeking Alpha • Oct 21
Nuvation Bio: Competitive Data In ROS1+ NSCLC, Strong Cash, Smallish Market
Summary Nuvation Bio's Taletrectinib shows promising data in phase 2 trials for ROS1-positive NSCLC, outperforming current market leaders in key metrics like DOR and PFS. Despite a small target market, Taletrectinib's potential $1bn market opportunity and strong financials make NUVB a compelling investment ahead of its PDUFA. Risks include a competitive landscape with established drugs and emerging rivals like NVL-520, which could impact market share. With solid leadership and a strong cash position, NUVB is well-positioned for growth, making it a stock to watch closely. Read the full article on Seeking AlphaSeeking Alpha • Aug 08
Nuvation Bio: Continuing To Justify A Buy Thesis With Catalysts In 2024
Summary Nuvation Bio transitioned from early-stage to late-stage biotech with a near-approval, sitting at a $700 million market cap. The main project is taletrectinib, a novel ROS1 inhibitor with high response rates observed in studies, aiming for NDA filing. Financially stable with cash runway of 12-13 quarters, potential for accelerated approval of taletrectinib, but uncertainty in market adoption. Read the full article on Seeking AlphaAnaliz Makalesi • Aug 07
Is Nuvation Bio (NYSE:NUVB) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Jun 20
Nuvation Bio: A Potentially Transformative Acquisition
Summary Nuvation Bio stock has been on a roll since late October, as the shares have roughly tripled since then. The main driver of this rally is the potentially transformative acquisition of AnHeart Therapeutics. This greatly enhanced Nuvation's pipeline and prospects. Analyst firms have a universally positive outlook on the company and its equity as well. In addition, Nuvation is well-funded, with the majority of the stock's market cap represented in cash and marketable securities on the company's balance sheet. An analysis around Nuvation Bio follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Mar 31
Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate
Summary Nuvation Bio has acquired an advanced pipeline candidate, taletrectinib, leading to a surge in market cap approaching $1 billion. Taletrectinib has shown promising clinical activity in treating ROS1-positive non-small cell lung cancer and has Breakthrough Therapy Designation. Nuvation Bio also now has other pipeline candidates, including safusidenib and NUV-868, and has sufficient liquid assets to fund operations for years without help. Read the full article on Seeking AlphaGelir ve Gider Dağılımı
Gelir ve Gider Dağılımı
Nuvation Bio nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 26 | 170 | -150 | 159 | 129 |
| 31 Mar 26 | 143 | -146 | 154 | 126 |
| 31 Dec 25 | 63 | -205 | 152 | 115 |
| 30 Sep 25 | 27 | -217 | 137 | 110 |
| 30 Jun 25 | 14 | -203 | 120 | 109 |
| 31 Mar 25 | 11 | -606 | 97 | 111 |
| 31 Dec 24 | 8 | -568 | 69 | 99 |
| 30 Sep 24 | 2 | -532 | 49 | 85 |
| 30 Jun 24 | 1 | -511 | 37 | 76 |
| 31 Mar 24 | 0 | -69 | 28 | 65 |
| 31 Dec 23 | 0 | -76 | 29 | 71 |
| 30 Sep 23 | 0 | -83 | 31 | 73 |
| 30 Jun 23 | 0 | -90 | 31 | 76 |
| 31 Mar 23 | 0 | -105 | 32 | 86 |
| 31 Dec 22 | 0 | -104 | 32 | 88 |
| 30 Sep 22 | 0 | -108 | 32 | 89 |
| 30 Jun 22 | 0 | -103 | 30 | 85 |
| 31 Mar 22 | 0 | -88 | 27 | 70 |
| 31 Dec 21 | 0 | -87 | 24 | 65 |
| 30 Sep 21 | 0 | -75 | 21 | 56 |
| 30 Jun 21 | 0 | -64 | 18 | 48 |
| 31 Mar 21 | 0 | -53 | 14 | 41 |
| 31 Dec 20 | 0 | -42 | 11 | 33 |
| 30 Sep 20 | 0 | -38 | 8 | 32 |
| 30 Jun 20 | 0 | -32 | 7 | 27 |
| 31 Mar 20 | 0 | -33 | 7 | 26 |
| 31 Dec 19 | 0 | -34 | 7 | 25 |
Kaliteli Kazançlar: NUVB şu anda kârlı değil.
Büyüyen Kar Marjı: NUVB şu anda kârlı değil.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: NUVB kârlı değildir ve zararlar son 5 yılda yılda 27.1% oranında artmıştır.
Büyüme Hızlandırma: NUVB 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil
Kazançlar vs. Sektör: NUVB kârlı olmadığından, geçmiş yıl kazanç büyümesinin Pharmaceuticals sektörüyle ( 1% ) karşılaştırılması zorlaşıyor.
Özkaynak Getirisi
Yüksek ROE: NUVB hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -59.02% ) sahiptir.
Varlık Getirisi
Kullanılan Sermaye Getirisi
Geçmişte güçlü performans gösteren şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/09/14 18:08 |
| Gün Sonu Hisse Fiyatı | 2026/09/14 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Nuvation Bio Inc. 16 Bu analistlerden 12, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Clarence Powell | BMO Capital Markets Equity Research |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Li Wang Watsek | Cantor Fitzgerald & Co. |